Minocycline/tetracycline is clinically used for the treatment of bullous pemphigoid (BP), and its clinical benefits are superior to those of prednisolone when considering adverse events. Although the clinical benefits of minocycline/tetracycline are well known, its immunosuppressive mechanisms are still unclear. In this study, we investigated the immunomodulatory effects of traditional anti-BP drugs (minocycline, nicotinic acid amide, dexamethasone and cyclosporine) on CD163 + M2 macrophages in vitro, with special focus on the production of CCL18 and CCL22, both of which are produced by CD163 + M2 macrophages in the lesional skin of BP and are increased in the serum of BP patients. Minocycline decreased the production of CCL22, CCL24
| INTRODUC TI ON
Bullous pemphigoid (BP) is an autoimmune blistering disease predominantly affecting the elderly, and various drugs such as nicotinic acid amide (NAA), minocycline/tetracycline, dexamethasone and cyclosporine have been clinically used for its treatment. [1, 2] Recently, Williams et al [1] reported that the clinical benefits of doxycycline are superior to those of prednisolone when considering adverse events.
In Japan, minocycline is also used for the treatment of BP instead of doxycycline. [2] Although numerous clinical benefits of minocycline/ tetracycline have been reported, its immunosuppressive mechanisms are still largely unknown.
Macrophages are functionally polarized into M1 and M2 cells in response to the immune microenvironment in lesional skin. [3] M2 macrophages promote the recruitment of Th2 cells in the skin, leading to the development of a Th2-polarized microenvironment in various skin diseases, such as atopic dermatitis, eosinophilic disorders and BP. [4] [5] [6] [7] Therefore, M2 macrophages are a potential target for Th2-related skin inflammatory diseases. [6, 7] In this study, we investigated the immunomodulatory effects of anti-BP drugs (minocycline, nicotinic acid amide, dexamethasone and cyclosporine) in vitro on CD163 + M2 macrophages, which are the predominant macrophage phenotype in the lesional skin of BP.
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| MATERIAL S AND ME THODS

| Reagents
The following antibodies were used for immunofluorescence: mouse 
| Tissue samples and immunohistochemical staining
Archival frozen skin specimens in optimal cutting temperature embedding medium (Sakura Finetek Japan Co. Ltd., Tokyo, Japan)
were collected from three patients with BP at the initial visit who were treated in the Department of Dermatology at Tohoku University Graduate School of Medicine. This part of the study was approved by the ethics committee of the Tohoku University
Graduate School of Medicine, Sendai, Japan (2017-1-376). All patients provided informed consent. All cases of BP showed increased levels of serum BP180 or deposition of IgG and C3 in the basement membrane zone in epidermal lesions detected by direct immunofluorescence.
| Tissue samples and immunofluorescence staining
For cryosections, each sample was frozen in optimal cutting temperature embedding medium, and 6-μm sections were fixed with cold acetone for 30 min and blocked with IF buffer (PBS, 5% bovine serum albumin). Thereafter, each section was incubated with relevant antibodies. The slides were mounted in DAPI Fluoromount-G (Southern Biotech, Birmingham, AL) and examined using a Zeiss LSM 700 microscope equipped with a SPOT digital camera.
| Chemokine ELISA
We analyzed serum levels of CCL17, CCL18, CCL22 and CXCL10
in seven patients with BP and pemphigus vulgaris (PV) at the initial visit ( /mL) were cultured in complete medium containing 100 ng/mL of recombinant human M-CSF for 5 days as previously reported. [8] On the fifth day, monocyte-derived M2 macrophages were treated with NAA
(1 μg/mL), minocycline (1 μg/mL), dexamethasone (1 μg/mL) or CyA
(1 μg/mL). The concentrations of each drug were determined using the C max of each drug. [9, 10] This part of the study was approved by the ethics committee of the Tohoku University Graduate School of Medicine, Sendai, Japan (2017-1-1045).
| Statistical analysis
For a single comparison of two groups, the Mann-Whitney U test was used. The level of significance was set at P < 0.05.
| RE SULTS
| Serum levels of CCL17, CCL22 and CXCL10 in BP patients
As previous reports suggested, serum CXCL10 [11] is significantly increased in BP patients. In addition, as we previously reported, [4, 12] CD163 + M2 macrophages are stimulated by periostin (POSTN) and IL-4, leading to activation and the production of a series of chemokines, including Th2-related chemokines (CCL17, TA B L E 1 BP and PV patient characteristics and serum levels of anti-BP180 Ab, anti-Dsg1 Ab and anti-Dsg3 Ab CCL18, CCL22, CCL24 and CCL26). [13] Guenter et al [14] suggested that the serum levels of CCL18 correlate with the disease severity of BP. In addition, the serum levels of soluble CD163 (sCD163) are significantly increased in BP patients as compared to healthy donors, suggesting that CD163 + macrophages are activated in patients with BP, whereas there is no significant difference in serum CXCL5 or proinflammatory chemokines in BP compared to healthy donors. [12] Given these reports, we first examined the serum levels of CCL17, CCL22 and CXCL10, all of which are increased in CD163 + M2 macrophages by stimulation with POSTN and IL-4 [13] in patients with BP as well as healthy donors according to ELISA.
The serum levels of CCL17, CCL18 and CCL22 were significantly increased in BP patients as compared to PV patients and healthy donors ( Figure 1 ). CXCL10 was significantly increased in BP patients and PV patients as compared to healthy donors ( Figure 1 ).
Spearman's rank coefficient analysis revealed that there was no significant correlation between the serum levels of chemokines and anti-BP180 Ab levels. In addition, CXCL10 expression on keratinocytes was increased in the lesional skin of BP compared to that of eczematous dermatitis ( Figure S1 ).
| CD163 + tissue-associated macrophages produce CCL18 and CCL22, but not CCL17 and CXCL10, in the lesional skin of BP
Since the serum levels of CCL18 correlate with disease severity of BP, [8] and CCL22 and CXCL10 are increased in patients with BP, we hypothesized that M2 macrophages might produce CCL17, CCL18, Figures 1 and 2 and a previous report, [12] M2 macrophages produce CCL18 and CCL22 in the lesional skin of BP, leading to a significant increase in serum CCL18 and CCL22. Since NAA, minocycline, dexamethasone and cyclosporine have been clinically used for the treatment of BP, [1, 2, 14] we hypothesized that these drugs might affect the production of chemokines from CD163 + M2 macrophages. To test this, we evaluated the production of chemokines from CD163 + M2 macrophages using M2 macrophages generated from PBMCs in healthy donors. [8, 15] The production of CCL22 was significantly decreased by NAA, minocycline, dexamethasone or cyclosporine, whereas CCL18 was significantly decreased by dexamethasone or cyclosporine (Figure 3) . NAA or minocycline did not affect the production of CCL18. As we expected given the results shown in Figure 2 , the production of CCL17 was not suppressed by minocycline or cyclosporine (Figure 3 ). NAA and dexamethasone, respectively, increased the production of CCL17 from M2 macrophages ( Figure 3 ).
We also evaluated other Th2 chemokines (CCL24 and CCL26) that might contribute to the pathogenesis of BP by the recruitment of eosinophils, [8, 11, 15, 16] and CCL2, which is reported to recruit the precursor of macrophages [17] and is increased in the serum of BP patients. [6] Minocycline and cyclosporine, respectively, significantly decreased the production of CCL2, CCL24 and CCL26 from M2 macrophages ( Figure 3 ). In contrast, dexamethasone only increased the production of CCL24 from M2 macrophages (Figure 3 ). 
| D ISCUSS I ON
Bullous pemphigoid is an autoimmune blistering disease and is reported to correlate with Th2 cells. [18, 19] In addition, as we previously reported, substantial numbers of CD163 + M2 polarized M2 macrophages are detected in the lesional skin of BP. [5, 12] Since M2 macrophages can produce specific chemokines by stimulation with stromal factors in the skin to induce the polarization of helper T subsets in the microenvironment of various skin diseases, [20] serum chemokines have been used as predictable markers for the disease severity of BP. [14, 21, 22] Günther et al [14] reported that serum CCL18 levels are correlated with the disease course in most patients.
Moreover, Nakashima et al [11] previously investigated 10 chemokines (CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CXCL1, CXCL9 and CXCL10) in BP patients and suggested that increased levels of CCL2 and CXCL10 might contribute to the pathogenesis of BP, though they did not discover the source of these chemokines. In our present study, CCL18 was significantly increased in serum from BP patients compared with healthy donors, and it was produced by CD163 + M2 macrophages in the lesional skin of BP. In contrast, although CXCL10 was significantly increased in serum from BP patients compared with healthy donors, CD163 + M2 macrophages did not produce CXCL10
in the lesional skin of BP. The increased levels of serum CXCL10 might correlate with other organs in BP patients. In contrast to previous studies, there was no significant correlation between the serum levels of CCL18 and CXCL10 and anti-BP180 Ab levels, which we used to represent BP disease activity instead of the BP Disease Area
Index. Further studies are therefore needed to demonstrate a correlation between these chemokines and the disease activity of BP.
In addition to CCL18 and CXCL10, our previous study suggested that CD163 + M2 macrophages might increase the production of Th2 chemokines, including CCL17 and CCL22, by stimulation of IL-4 with POSTN. [4, 12, 13] Both CCL17 and CCL22 are ligands of CCR4, suggesting the recruitment of Th2 and regulatory T cells in lesional skin. [23] Since Th2 contributes to the pathogenesis of BP, [24, 25] we hypothesized that CCL17 and CCL22 produced by CD163 M2 macrophages increase serum CCL17 and CCL22 levels in BP patients. In our present study, serum CCL22 was increased in BP patients compared with healthy donors, and CD163 + M2 macrophages produced CCL22 in the lesional skin of BP. Moreover, the production of CCL22 from M2 macrophages was significantly decreased by minocycline, suggesting that the therapeutic effects of minocycline might be, at least in part, due to its suppressive effects on the production of CCL22 from M2 macrophages. In addition, in contrast to CCL22, although serum CCL17 was increased, CD163 + M2 macrophages did not produce CCL17 in the lesional skin of BP. This discrepancy might be caused by the activation phase of M2 macrophages. [20] Indeed, M2 macrophages need to be fully activated by stromal factor after M2 polarization to produce substantial levels of CCL17. [8, 20] Since CCL17
can be produced from other cells, such as Langerhans cells, blood endothelial cells, platelet cells and fibroblasts, [26] the increased levels of serum CCL17 might have been caused by these cells. Although chemokines are produced not only by M2 macrophages but also by other myeloid cells such as Langerhans cells, [27] chemokines in this study might have been mainly produced by M2 macrophages, as suggested by a previous report.
[ 27] Since we did not assess other myeloid cells, further studies are needed.
Given the above findings, we further investigated the immunomodulatory effects of minocycline as well as NAA, dexamethasone and cyclosporine on CD163 + M2 macrophages using CD163 + M2 macrophages in vitro, focusing especially on the production of CCL18 and CCL22, both of which were produced by CD163 + M2 macrophages in the lesional skin of BP and increased in the serum in BP patients. Interestingly, the serum levels of CCL18 and CCL22 in BP patients were significantly higher than those in PV patients. Notably, minocycline is clinically effective for BP but not PV. Minocycline decreased the production of CCL22, CCL24 and CCL26 as well as CCL2 from M2 macrophages. CCL18 from M2 macrophages was decreased by dexamethasone and cyclosporine, but not decreased by minocycline. Since we treated BP patients by a combination therapy of prednisolone, minocycline and NA, we could not directly evaluate the immunomodulatory effects of minocycline in BP patients. These data suggested that the clinical benefit of minocycline is partially explained by its suppressive effects on the production of specific Th2 chemokines from M2 macrophages, which should contribute to the recruitment of Th2 cells and eosinophils in the lesional skin of BP.
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